Full Press Release Details
Aurora Completes First-Ever EU-GMP Certification
for the Company's Dedicated Distribution Centre
Adding a fourth certified facility
within its global network increases operational capacity to better serve international medical markets
EDMONTON, AB, July 14, 2025 /CNW/ - Aurora Cannabis
Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that its dedicated distribution
centre located in Brampton, Ontario, has received European Union Good Manufacturing Practice ("EU-GMP") certification, increasing
the company's international export capabilities. The distribution centre joins Aurora's group of manufacturing facilities in Canada and
Europe certified against EU standards, demonstrating the company's unwavering commitment to regulatory excellence, end-to-end operational
quality assurance, and global supply chain efficiency.
"Securing EU-GMP certification at manufacturing
and distribution facilities within our network is an important validation of our differentiated approach to operating as a global medical
cannabis company," said Jill Lau, Vice President of Canadian Operations at Aurora. "By adding certification for our distribution
centre, we are now uniquely positioned to ensure patients worldwide have consistent access to superior quality medical cannabis from the
largest Canadian exporter."
EU-GMP certification is granted to companies whose
production facilities meet the requirements under the EudraLex "Rules Governing Medicinal Products in the European Union," and
that can demonstrate a high degree of quality and consistency in their manufacturing procedures, a requirement for the export of medical
cannabis products into Europe. EU-GMP certification of the company's distribution centre allows it to serve as a centralized site for
more optimized and efficient receipt, storage and distribution of materials and finished products internationally.
With operations across Canada and in Europe, Aurora
remains at the forefront of the global medical cannabis industry. By continuously investing in operational capabilities, regulatory excellence,
and a science-led approach, Aurora is best positioned to deliver high-quality medical cannabis that meets and exceeds the highest international
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both
the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer
in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael
'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana
Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North
America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis
products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever
Aurora's common shares trade on the NASDAQ and TSX
under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project",
"intend", "believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur.
Forward-looking statements made in this news release include, but are not limited to, statements regarding the EU-GMP certification for
the Company's dedicated distribution centre and benefits for the Company, including increases to operational capacity for international
medical markets; statements regarding the Company's ability to meet patient demand globally; and the Company's commitment to regulatory
excellence, end-to-end operational quality assurance and global supply chain efficiency.
These forward-looking statements are only predictions.
Forward looking information or statements contained in this news release have been developed based on assumptions management considers
to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from market research and industry analysis and on assumptions based on data
and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks,
uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events,
results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking
statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods
imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure
to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and
retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand
in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration
of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability
to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield
from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes
in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and
factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF")
and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with
and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described
in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties
and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-completes-first-ever-eu-gmp-certification-for-the-companys-dedicated-distribution-centre-302503683.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2025/14/c4861.html
For further information: For Media: Michelle Lefler, VP, Communications
& PR, media@auroramj.com; For Investors: ICR, Inc., aurora@icrinc.com
CO: Aurora Cannabis Inc.
CNW 07:00e 14-JUL-25